澳股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

NEUREN PHARMACEUTICALS LTD

12.625

+0.1951.57%

成交量：25.28萬

成交額：316.02萬

市值：16.04億

市盈率：11.62

高：12.730

開：12.600

低：12.265

收：12.430

資料載入中...

總覽公司新聞資訊公告

概念

醫藥生物股-0.88%

資金流向

資金流入：

資金流出：

新聞資訊

BUZZ-Neuren 製藥公司在美國合作伙伴出售 FDA 審查券後成為行業標杆

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/NEU.AU"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NEU.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","market":"AU","secType":"STK","nameCN":"NEUREN PHARMACEUTICALS LTD","latestPrice":12.625,"timestamp":1741232186634,"preClose":12.43,"halted":0,"volume":252847,"delay":0,"changeRate":0.015688,"change":0.195,"floatShares":110014206,"shares":127012624,"eps":1.086099,"lyrEps":1.111713,"pbRate":4.41,"amount":3160188,"amplitude":0.037409,"volumeRatio":0.402234,"dividePrice":0,"prevYearClose":12.5,"fiveDayClose":14.2,"twentyDayClose":13.93},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","floatShares":110014206,"roa":"34.05%","roe":"49.92%","lyrEps":1.111713,"volumeRatio":0.402234,"shares":127012624,"dividePrice":0,"high":12.73,"amplitude":0.037409,"preClose":12.43,"low":12.265,"week52Low":10.9,"pbRate":"4.41","psRate":"7.40","week52High":24,"institutionHeld":0,"latestPrice":12.625,"committee":0.526471,"eps":1.086099,"divideRate":0,"volume":252847,"delay":0,"ttmEps":1.086099,"open":12.6,"prevYearClose":12.5,"prevWeekClose":13.23,"prevMonthClose":13.23,"prevQuarterClose":12.5,"fiveDayClose":14.2,"twentyDayClose":13.93,"sixtyDayClose":12.8},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NEU.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740697200000,"name":null,"time":"","dateTimestamp":1740661200000,"actualEps":null},{"market":"AU","date":"2024-02-29","symbol":"NEU.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1709125200000,"reportTimeType":"","actualEps":null},{"date":"2023-08-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693180800000,"name":null,"time":"","dateTimestamp":1693144800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NEU.AU\",market:\"AU\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NEU.AU\",params:#limit:6,delay:false,,,undefined,":[{"market":"AU","name":"醫藥生物股","bkCode":"BK7508","id":"package_au_concept_yyswg","changeRate":-0.008801}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NEU.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2481669512","title":"BUZZ-Neuren 製藥公司在美國合作伙伴出售 FDA 審查券後成為行業標杆","url":"https://stock-news.laohu8.com/highlight/detail?id=2481669512","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481669512?lang=zh_tw&edition=fundamental","pubTime":"2024-11-06 07:42","pubTimestamp":1730850153,"startTime":"0","endTime":"0","summary":"    11月5日 - ** 澳大利亚Neuren制药公司  股价上涨6%至13.00澳元，创下自9月27日以来的最大盘中涨幅。** NEU 在 ASX200 基准指数    中涨幅最大** 开发神经发育障碍疗法的 NEU 公司表示， ，其美国合作伙伴 ACADIA 制药公司  将以 1.5 亿美元的价格出售罕见儿科疾病优先审查券。** 获得美国 FDA 授予的罕见儿科疾病药物 PRV 的实体可以使用该凭证获得另一种产品的优先审评权** FDA 在批准 DAYBUE 用于治疗罕见遗传性神经系统疾病 Rett 综合征后授予了 PRV。","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","NEU.AU","LU2065170008.USD","LU2065169927.USD","BK7096","ACAD","BK4139","BK7508","LU2065171402.SGD"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":1}]}}